You are not currently logged in.
Access JSTOR through your library or other institution:
Antimicrobial Chemotherapy for Legionnaires' Disease: A Review
Paul H. Edelstein
Clinical Infectious Diseases
Vol. 21, Supplement 3. Bacterial Pneumonia: Pathogenesis, Pathogens, Diagnosis, and Treatment (Dec., 1995), pp. S265-S276
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4459154
Page Count: 12
You can always find the topics here!Topics: Legionnaires disease, Antimicrobials, Legionella, Epidemiology, Pneumonia, Mortality, Legionella pneumophila, Disease susceptibility, Disease models, Diseases
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Controlled trials of antimicrobial chemotherapy for legionnaires' disease have not been performed, although erythromycin and tetracycline appear to be effective therapies. Laboratory data indicate that the activities of the fluoroquinolone and newer macrolide/azalide agents against Legionella pneumophila are superior to that of erythromycin, and case reports substantiate that the activities of these agents are at least equal. Results of clinical treatment with and laboratory testing of macrolides, tetracyclines, co-trimoxazole, chloramphenicol, aminoglycosides, fluoroquinolones, β-lactam agents, and streptogramins are reviewed. The drugs of choice for the treatment of legionnaires' disease in immunocompromised or severely ill patients should be one of the fluoroquinolone antimicrobials rather than erythromycin.
Clinical Infectious Diseases © 1995 Oxford University Press